Posted in Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint April 17, 2026 BioSpace More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed. Clinical DataMetabolic & GLP-1Read full story